Impact of an Artificial Intelligence Platform on Inappropriate Medication Use in Older Adults

NCT ID: NCT04710615

Last Updated: 2024-02-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-05

Study Completion Date

2024-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Polypharmacy in the older adults is common and promotes the risk of drug interactions. The hypothesis evoked is that a virtual platform with artificial intelligence applied to the health, and in particular to the good use of the drug, could bring aids to the doctors them of the prescription of drugs. The main objective of this study is to evaluate the impact of geriatric use of the Synapse platform on the frequency of inappropriate medication prescriptions (STOPP criteria) in discharge orders for patients 65 years of age or older hospitalized in geriatric department.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The French 2018-2022 National Health Strategy plan aims to reduce the proportion of potentially harmful medication use. One particular challenge is the phenomenon of polypharmacy and inappropriate medication use in elderly, which is associated to an increased risk of drug-drug interactions. Several scales and tools have been proposed to identify inappropriate drugs prescription in older adults. Among them, the STOPP / START criteria (Screening Tool of Older Persons' Prescriptions / Screening Tool to Alert to Right Treatment) are internationally recognized.

The Synapse platform offers a panel of functions that may help physicians to prescribe medications. For instance, the prescriber can interact with the Synapse platform by asking any type of question about a drug (dosage, contraindication, interaction ...) before prescription. It also allows them to take a picture of prescription. The software detects in less than 10 seconds criteria for inappropriate medication prescriptions and potential drug-drug interactions.

More precisely, the Synapse platform provides information on a particular drug or prescription analysis regarding:

* Indications, contraindications, dosage and adverse effects of drugs.
* STOPP criteria.
* START criteria.
* Associations at risk for drug-drug interactions.

Multiple new health technologies are emerging, but few of them have demonstrated their scientific and medical added value using an evidence-based medicine approach.

This clinical trial aims to validate the clinical interest of the Synapse application in a geriatric environment.

Prescriptions made by geriatricians participating in this study will be analyzed by two independent experts, including one pharmacist and one geriatrician.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug-drug Interactions Geriatric Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Assistance device

With prescription assistance device:

During the other 3 months, investigators will have the Synapse platform on different media (mobile phones, tablets, laptops and landline).

Group Type EXPERIMENTAL

Synapse platform

Intervention Type DEVICE

The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.

The Synapse platform offers a panel of functions to help the doctor to prescribe medication.

No device

During 3 months, investigators will not have the Synapse platform and will make their prescriptions with the usual tools which they have: Modules of help in the DxCare® software of the CHU, public database of the drugs, dictionary Vidal®, …

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Synapse platform

The Synapse platform made available to health professionals, is a virtual assistant capable of understanding the questions of natural language doctors and providing an answer by specifying the source of information used. This device also allows you to photograph a prescription and analyze it automatically to detect potential drug interactions.

The Synapse platform offers a panel of functions to help the doctor to prescribe medication.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female age aged more than 65 years
* Hospitalization in geriatric department at Bordeaux University Hospital or Libourne Hospital
* Initial drug prescription with at least 2 active pharmaceutical ingredients
* Affiliation to French social security
* Written informed consent signed by participant and investigator

Exclusion Criteria

* Adults protected by law
* Subject included in a clinical trial with an experimental treatment
* Subject during exclusion period relative to another trial
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Bordeaux

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pierre-Olivier GIRODET, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Bordeaux

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de Bordeaux, Hôpital Pellegrin

Bordeaux, , France

Site Status RECRUITING

CHU de Bordeaux

Bordeaux, , France

Site Status RECRUITING

Centre Hospitalier de Libourne - Pôle Gériatrie

Libourne, , France

Site Status RECRUITING

CHU de Bordeaux, Hôpital Xavier Arnozan

Pessac, , France

Site Status RECRUITING

CHU de Bordeaux, Hôpital Xavier Arnozan

Pessac, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pierre-Olivier GIRODET, MD, PhD

Role: CONTACT

+335 57 57 15 60

Karelle FOREST

Role: CONTACT

+335 57 57 46 66

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Claire ROUBAUD-BAUDRON, MD, PhD

Role: primary

+335 56 82 18 44

Fabrice BONNET, MD, PhD

Role: primary

+335 56 79 58 26

Elsa ESTAQUE, MD

Role: primary

+335 57 55 16 03

Claire ROUBAUD-BAUDRON, MD, PhD

Role: primary

+335 56 82 18 44

Nathalie SALLES, MD, PhD

Role: primary

+335 57 65 65 53

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHUBX 2019/33

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug Interactions in Outpatients.
NCT03943524 SUSPENDED NA